Bristol Myers Squibb Company $BMY Shares Sold by Cooper Financial Group

Cooper Financial Group decreased its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY) by 17.8% during the 2nd quarter, Holdings Channel.com reports. The fund owned 13,031 shares of the biopharmaceutical company’s stock after selling 2,821 shares during the period. Cooper Financial Group’s holdings in Bristol Myers Squibb were worth $603,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently bought and sold shares of BMY. Brighton Jones LLC raised its stake in Bristol Myers Squibb by 33.4% during the fourth quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock worth $1,116,000 after acquiring an additional 4,935 shares during the period. NBC Securities Inc. grew its position in Bristol Myers Squibb by 102,110.0% in the 1st quarter. NBC Securities Inc. now owns 10,221 shares of the biopharmaceutical company’s stock worth $623,000 after purchasing an additional 10,211 shares during the last quarter. Merit Financial Group LLC grew its position in Bristol Myers Squibb by 21.6% in the 1st quarter. Merit Financial Group LLC now owns 51,601 shares of the biopharmaceutical company’s stock worth $3,147,000 after purchasing an additional 9,166 shares during the last quarter. RFG Advisory LLC grew its position in Bristol Myers Squibb by 67.1% in the 1st quarter. RFG Advisory LLC now owns 27,915 shares of the biopharmaceutical company’s stock worth $1,703,000 after purchasing an additional 11,208 shares during the last quarter. Finally, Bremer Bank National Association bought a new position in Bristol Myers Squibb in the 1st quarter worth about $200,000. Institutional investors and hedge funds own 76.41% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. Daiwa America cut shares of Bristol Myers Squibb from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 5th. Citigroup decreased their target price on shares of Bristol Myers Squibb from $51.00 to $47.00 and set a “neutral” rating for the company in a research report on Friday, August 1st. Wall Street Zen cut shares of Bristol Myers Squibb from a “strong-buy” rating to a “buy” rating in a report on Friday, June 6th. Morgan Stanley reiterated a “hold” rating on shares of Bristol Myers Squibb in a report on Thursday, July 31st. Finally, Daiwa Capital Markets cut shares of Bristol Myers Squibb from an “outperform” rating to a “neutral” rating and set a $42.00 price objective for the company. in a report on Tuesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fifteen have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Bristol Myers Squibb presently has a consensus rating of “Hold” and a consensus price target of $56.38.

Insider Buying and Selling at Bristol Myers Squibb

In other news, EVP David V. Elkins sold 56,000 shares of the firm’s stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $47.33, for a total transaction of $2,650,480.00. Following the transaction, the executive vice president owned 167,379 shares in the company, valued at approximately $7,922,048.07. This trade represents a 25.07% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 0.09% of the company’s stock.

Bristol Myers Squibb Trading Up 5.1%

Bristol Myers Squibb stock opened at $47.39 on Thursday. The company has a 50 day moving average price of $46.49 and a 200 day moving average price of $48.85. Bristol Myers Squibb Company has a 52 week low of $42.96 and a 52 week high of $63.33. The company has a debt-to-equity ratio of 2.54, a quick ratio of 1.11 and a current ratio of 1.21. The firm has a market capitalization of $96.47 billion, a price-to-earnings ratio of 19.11, a P/E/G ratio of 2.31 and a beta of 0.33.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $1.46 EPS for the quarter, topping analysts’ consensus estimates of $1.07 by $0.39. Bristol Myers Squibb had a net margin of 10.58% and a return on equity of 80.04%. The firm had revenue of $12.27 billion during the quarter, compared to analyst estimates of $11.32 billion. During the same quarter last year, the business posted $2.07 EPS. The company’s revenue was up .6% on a year-over-year basis. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS. Research analysts forecast that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, November 3rd. Stockholders of record on Friday, October 3rd will be issued a dividend of $0.62 per share. The ex-dividend date is Friday, October 3rd. This represents a $2.48 dividend on an annualized basis and a dividend yield of 5.2%. Bristol Myers Squibb’s dividend payout ratio (DPR) is currently 100.00%.

Bristol Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.